Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Amortization of Deferred Charges: 2021-2025

Historic Amortization of Deferred Charges for Heron Therapeutics (HRTX) over the last 4 years, with Sep 2025 value amounting to $2,000.

  • Heron Therapeutics' Amortization of Deferred Charges fell 96.23% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $161,000, marking a year-over-year decrease of 22.60%. This contributed to the annual value of $210,000 for FY2024, which is 1.94% up from last year.
  • Heron Therapeutics' Amortization of Deferred Charges amounted to $2,000 in Q3 2025, which was down 96.23% from $53,000 recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Amortization of Deferred Charges peaked at $55,000 during Q3 2023, and registered a low of $2,000 during Q3 2025.
  • Its 3-year average for Amortization of Deferred Charges is $47,818, with a median of $52,000 in 2024.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first grew by 5.77% in 2023, then slumped by 96.23% in 2025.
  • Over the past 5 years, Heron Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $50,000 in 2021, then remained steady at $50,000 in 2022, then rose by 2.00% to $51,000 in 2023, then climbed by 3.92% to $53,000 in 2024, then slumped by 96.23% to $2,000 in 2025.
  • Its Amortization of Deferred Charges stands at $2,000 for Q3 2025, versus $53,000 for Q2 2025 and $53,000 for Q1 2025.